Hepatocellular carcinoma
Conditions
Interventions
TACE group :Ablation combined with TACE
HAIC group:Ablation combined with HAIC
Control group :Ablation
Sponsors
The Third Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with early recurrence (recurrence within 1 year) after radical resection of hepatocellular carcinoma; 2. Patients who can tolerate ablation therapy; 3. Patients with hepatocellular carcinoma who meet the clinical diagnostic criteria of the "Standards for the Diagnosis and Treatment of Primary Liver Cancer" or diagnosed by histopathological or cytological examination; 4. Non-diffuse liver cancer with less than 4 lesions in the liver and all less than 3 cm in diameter; 5. The gender of the patient is not limited, aged from 18 to 75 years; 6. The patient has no serious comorbidities, such as a history of hypertension, coronary heart disease and mental illness, and no history of serious allergies; 7. Liver function reaches Child-Pugh grade A or B, kidney function is normal, blood coagulation function is normal or corrected after treatment; 8. HBV DNA<2000 IU/ml (104 copies/ml); 9. Women of childbearing age must have a pregnancy test within 7 days before enrollment; 10. The patient has signed an informed consent form agreeing to participate in the trial study and can be followed up.
Exclusion criteria
Exclusion criteria: 1. The tumor of the liver is huge (>=60% liver volume) , with portal vein tumor thrombus or tumor thrombus invading other blood vessels; 2. Patients who have undergone distant metastasis; 3. Suffered from other uncured malignant tumors in the past or at the same time; 4. A history of gastrointestinal bleeding or a clear tendency to gastrointestinal bleeding in the past 6 months; 5. Abnormal coagulation function (INR>1.5 or prothrombin time (PT)>ULN+4 seconds), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy; 6. Those who are allergic to chemotherapy drugs; 7. The general condition is exhausted, and the expected survival period is <3 months; 8. Unable to complete the treatment plan due to various reasons, and lose follow-up within three months after joining the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;vital signs; | — |
Countries
China
Contacts
Public ContactLi Kai
The Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed